Table 1.
Baseline characteristics of the 234 patients
| Gender (men/women) | 150 (64%) 84 (36%) |
| Median age (range, years) | 64 (24–83) |
| Performance status | |
| 0–1 | 182 (77%) |
| >1 | 52 (23%) |
| Therapeutic regimen | |
| FOLFOX | 124 (53%) |
| FOLFIRI | 110 (47%) |
| Number of cycles of chemotherapy | |
| Median (range) | 9 (1–20) |
| Cases with toxicity grade 0–2 | 10 (3–20) |
| Cases with toxicity grade 3–4 | 8 (1–20) |
| Primary tumour localization | |
| Colon | 84 (36%) |
| Rectum – Sigma | 150 (64%) |
| Toxicity grade 3–4* | |
| Nausea | 34 (14.5%) |
| Diarrhoea | 54 (23%) |
| Neutropenia | 94 (40.2%) |
| Asthenia | 81 (34.6%) |
*
Patients who developed high toxicity only.